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Abstract 
 
Objective: To determine whether cognitive therapy (CT) is effective in reducing 
psychiatric symptoms experienced by people with schizophrenia spectrum disorders that 
have chosen not to take antipsychotic medication. 
Design: A two-site single-blind randomised controlled trial comparing CT plus 
treatment as usual (TAU) with TAU only. Participants were followed-up for a minimum 
of 9 and a maximum of 18 months. 
Setting: Diverse services at two UK sites 
Participants: 74 participants with schizophrenia spectrum disorders who had chosen 
not to take antipsychotic medication psychosis (aged 16-65 years; mean 31.47; SD 
12.27) were recruited. 37 were assigned to CT and 37 to TAU.  
Intervention: CT incorporated up to 26 sessions over 9 months (mean sessions = 
13.30) plus up to four booster sessions. 
Main outcome measures: Primary outcome was the Positive and Negative Syndrome 
Scale (PANSS) total score, which provides a continuous measure of psychiatric 
symptoms associated with schizophrenia spectrum disorders on the basis of a commonly 
used structured psychiatric interview.  
Results:  Changes in outcomes were analysed following the intention-to-treat principle, 
using random effects regression (a repeated-measures ANCOVA) adjusted for site, age, 
gender and baseline symptoms.  Psychiatric symptoms were significantly reduced in the 
group assigned to CT, in comparison with TAU, with an estimated between-group 
effect size of -6.52 (95% CI -10.79  to -2.25, p = 0.003). 
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Conclusions: CT significantly reduced psychiatric symptoms and appears safe and 
acceptable in people with schizophrenia spectrum disorders who have chosen not to take 
antipsychotic medication. A larger, definitive trial is required. 
Trial registration: This study is registered as International Standard Randomised 
Controlled Trial number 29607432. 
Key words: Schizophrenia; Cognitive therapy; Psychosis; antipsychotic medication 
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Introduction 
Antipsychotic medication is seen as the first line of treatment for schizophrenia 
and clinical guidelines suggest that there are clear benefits in terms of symptom 
reduction 1. In addition, recent studies have also shown that antipsychotic use is 
associated with decreased mortality overall 2, perhaps because of a protective effect 
against suicide 2, and have shown significant benefits for relapse prevention 3. However, 
there is also evidence that many service users choose to refuse or discontinue their 
pharmacological treatment. The largest trial 4 to compare atypical antipsychotics found 
that 74% of patients with a diagnosis of schizophrenia chose to discontinue their 
medication over 18 months and it is estimated that rates of medication non-compliance 
in schizophrenia can be as high as 40% to 50% 5. It is well known that service users 
with psychosis are often ambivalent about taking medication 6, and recent evidence 
suggests that the efficacy of such medication has been overestimated while the severity 
of their adverse effects have been underestimated. A recent systematic review 
concluded that the improvements claimed for antipsychotics, old and new, are of 
questionable clinical relevance 7, with most trials failing to demonstrate even minimal 
improvement using the PANSS, and a recent multiple-treatments meta-analysis 8 found 
that “although differences in efficacy were seen, they were smaller than those reported 
for most of the analysed adverse effects” 9. Recent research suggests that adverse effects 
include structural abnormalities in brain volume that have previously been attributed to 
the syndrome of schizophrenia 10, increased risk of sudden cardiac death 11 and 
substantial weight gain induced by antipsychotics 12, which is associated with 
cardiovascular and metabolic risks.  
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Given the cost-benefit profile outlined above, some choices to refuse 
antipsychotics may reflect a rational decision rather than an irrational consequence of 
psychosis. It is clear that many people hospitalised with psychosis retain treatment 
decision-making capacity 13, and a recent review regarding choice and decision making 
in people using mental health services concluded it is “abundantly clear that service 
users want to be offered more than just medication” 14. Cognitive therapy (CT) has been 
shown to be effective when delivered in combination with antipsychotic medication, 
with several meta-analyses showing robust support for this approach 15. Our recent 
exploratory single-arm trial study evaluated CT for people with psychotic disorders in 
20 participants with schizophrenia spectrum disorders who had not been taking 
antipsychotic medication for at least 6 months 16; we found significant beneficial effects 
on primary and secondary outcomes at end-of-treatment and follow-up, good 
acceptability and no patients significantly deteriorated. However, such a trial clearly 
suggests the possibility of bias resulting from allegiance effects and non-blind ratings, 
and the lack of randomisation to a control condition was also problematic; these 
methodological limitations probably resulted in inflated estimates of treatment effects, 
since CT for psychosis trials that attempt masking are associated with a reduction of 
effect sizes of nearly 60% 15. 
Therefore, our pilot study aimed to conduct an examination of the feasibility and 
effectiveness of CT for people with schizophrenia spectrum disorders who had decided 
not to take antipsychotic medication, under single-blind, randomised controlled 
conditions. Our primary hypothesis is that CT will be effective in reducing psychiatric 
symptoms, in comparison to TAU, within this population. We also hypothesised that CT 
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would reduce dimensions of delusional beliefs and voice hearing, reduce emotional 
dysfunction and improve real-life functioning and user-defined recovery.  
Methods 
Trial design: This is a two-site randomized, controlled, single-blind (rater) pilot trial 
comparing two conditions (CT plus TAU versus TAU control). Our protocol was 
approved by the National Research Ethics Service of the United Kingdom’s National 
Health Service (NREC: 09/H1014/53). 
Participants: Trial entry criteria were that participants were in contact with mental 
health services, and either met ICD-10 criteria for schizophrenia, schizoaffective 
disorder or delusional disorder or met entry criteria for an Early Intervention for 
Psychosis service (operationally defined using PANSS) in order to allow for diagnostic 
uncertainty in early phases of psychosis and the fact that most early episode cases 
within the UK will receive their services from such specialist teams, consistent with 
NICE guidelines. They also either had at least 6 months without antipsychotic 
medication and experiencing continuing symptoms or never had received antipsychotics 
and had chosen not to, and all scored at least 4 on PANSS delusions or hallucinations, 
or at least 5 on suspiciousness/ persecution, conceptual disorganisation or grandiosity. 
All participants were identified via care coordinators and relevant mental health staff 
within participating mental health trusts at our 2 sites (Manchester/North West and 
Newcastle/North East), and were aged 16-65. Exclusion criteria were current receipt of 
antipsychotic medication; moderate to severe learning disability; organic impairment; 
lacking capacity to consent to research participation; non-English speaking (since this 
would prevent the use of standardised assessment instruments); acute inpatient care 
settings; having received CT for psychosis or, previous CT for other disorders in the last 
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2 years; and a primary diagnosis of substance or alcohol abuse. Diagnosis was 
established using case notes and a standardised checklist (ICD-10); all diagnoses were 
confirmed by a Consultant Psychiatrist (DT), applying the ICD-10 checklist to vignettes 
based on the PANSS assessments for all cases, including those in early intervention 
services who did not have a formal diagnosis in their medical records. Diagnoses were 
as follows: schizophrenia n= 68 (91.9%), Schizoaffective n = 2 (2.7%), Persistent 
Delusional Disorder n = 3 (4.1%) and Psychosis Not Otherwise Specified n = 1 (1.4%). 
Further details regarding our ascertainment strategy, referral sources, reasons for 
choosing not to take antipsychotics and additional participant characteristics are 
provided elsewhere 17.  
Randomisation: Following the baseline assessment, participants were randomised 
electronically using a 1:1 ratio via OpenCDMS 18. The randomisation algorithm uses 
randomised permuted blocks with block sizes of four or six, after first stratifying by 
site. OpenCDMS then sent out email notification of the allocation to the therapists and 
trial manager. Thus, the results of the randomisation were concealed from the assessors 
and randomisation was independent. Participants were randomised to TAU or CT plus 
TAU. TAU will have been variable and dependent on local service configurations and 
specific source of referral to the trial; therefore, randomisation was stratified by site in 
an attempt to control for this variation. 
Interventions:  
CT plus TAU 
In addition to TAU (described below), participants allocated to the therapy arm 
of the trial received CT based on a specific cognitive model 19. 26 sessions were offered 
on an approximately weekly basis for up to a maximum of 9 months, plus up to four 
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booster sessions in the subsequent nine months. Cognitive therapy requires an 
individualised, problem-orientated approach and incorporates a process of assessment 
and formulation, which is manualised. The central features of our approach to treatment 
of psychosis involves normalising and evaluating the appraisals that people make, 
helping them test out such appraisals using behavioural experiments and helping them 
to identify and modify unhelpful cognitive and behavioural responses. A more detailed 
analysis of the treatment strategies can be found in our treatment manuals 20 21. Fidelity 
to the treatment protocol was ensured by regular supervision of the therapists and 
assessed by rating recordings of sessions using a version of the Cognitive Therapy 
Scale-Revised 22 (CTS-R) and reviewing written, structured session records that were 
completed by the therapist after each session. Therapy supervision was provided by 
means of regular meetings between therapists and the chief investigator. A total of ten 
sessions were rated on the CTS-R, and all were rated as competent or above. 
CT Therapists 
In total, 8 therapists contributed to the delivery of CT within the trial. The 
number of participants treated by each ranged between 2 and 18 (mean = 4.6, SD = 5.5). 
Sites varied as follows: Manchester/North West (2 therapists), Newcastle/North East 
(6). 5 were clinical psychologists (doctoral level), 2 were nurses with an additional 
specialist CT qualification and 1 was a Consultant Psychiatrist with specialist training in 
CT. All received additional training associated with the trial manual and received 
regular supervision.  
TAU 
All participants received treatment as usual plus regular monitoring 
(incorporating a PANSS assessment from a research assistant), which represents an 
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enhancement over routine care since it aimed to provide warm, empathic and non-
judgemental face-to-face contact, supportive listening, signposting to appropriate local 
services for unmet needs and crisis management when required (usually by referral to a 
local crisis team, early intervention service or psychiatric liaison within emergency 
departments). Treatment as usual was variable across both sites, although both sites 
were chosen in part because they had comprehensive early intervention services (EIS). 
In practice, those within EIS (n=43/74: 58.1%) received regular care-coordination and 
psychosocial interventions including the offer of family interventions, whereas those 
from other community based services often received little other than irregular contact 
with care coordinators, and many of these were discharged by these teams within the 
lifetime of the trial for non-attendance on continued reluctance to accept medication. 
Outcomes: Our primary outcome measure was the total score on the Positive and 
Negative Syndromes Scale (PANSS: 23, which is a clinician administered thirty-item 
semi-structured interview consisting of seven items assessing positive symptomatology 
(e.g. hallucinations, delusions, conceptual disorganisation), seven items assessing 
negative symptomatology (e.g. blunted affect, passive/apathetic social avoidance) and 
sixteen items assessing general psychopathology (e.g. depression, anxiety, lack of 
insight, guilt). All items are scored between 1 (not present) and 7 (severe). A number of 
studies have demonstrated the reliability and validity of the PANSS 24. Inter-rater 
reliability of the PANSS assessments was assessed regularly (on 9 occasions) over the 
lifetime of the trial, using both video and role-play assessments with all trial raters (n=5) 
participating; intra-class correlation coefficients indicated good reliability between 
raters (mean = 0.83, S.D. = 0.12). 
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Secondary outcomes included dimensions of psychotic experiences such as 
severity, distress and disability, measured using the Psychotic Symptom Rating Scales 
25, which is a clinician administered semi-structured interview consisting of eleven 
items assessing dimensions of auditory hallucinations and six items assessing 
dimensions of delusional beliefs. All items are scored 0 to 4, with higher scores 
indicating more severe phenomena. Factor analyses show the delusions scale has two 
subscales (emotional and cognitive) and the hallucinations scale has three subscales 
(emotional, physical and cognitive) 25. We also included a user-defined measure of 
recovery (QPR 26), which is a questionnaire developed collaboratively with service 
users, measuring subjective recovery ; we employed a 15 item version that has been 
shown to be more reliable than the original 22 item version (Cronbach’s alpha in our 
sample was 0.91, showing good internal consistency). Participants rate their agreement 
with statements on a 5 point Likert scale rating from “strongly disagree” to “strongly 
agree”. Social functioning was assessed using the Personal and Social Performance 
Scale 27, which is a 100–point single-item rating scale based on an interview that 
assesses patient's functioning in four areas (socially useful activities, personal and social 
relationships, self-care and disturbing and aggressive behaviour). We assessed 
emotional distress using the Beck Depression Inventory for Primary Care (BDI-PC) 28 
and the Social Interactions Anxiety Scale (SIAS) 29. The SIAS has a recommended cut-
off of greater than 36, indicating a probable diagnosis of social anxiety disorder30, and 
the BDI-PC has a recommended cut-off of greater than 3, indicating a probable 
diagnosis of major depressive disorder28. We recorded prescriptions of antipsychotic 
and other psychiatric medications. Most assessments occurred in the participants’ home. 
Several other measures were administered (such as EQ5D, the CHOICE, the 
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Metacognitions Questionnaire and the Personal Beliefs about Experiences 
Questionnaire), but these were intended for secondary analyses such as predictors of 
outcome and cost effectiveness; we report on all outcomes that were specified in our 
published protocol and analysis plan 17. 
Post-randomisation, all participants received monitoring assessments every three 
months up to a total of 18 months. Our variable follow-up period means that 
participants recruited in the first 18 months of the study (from February 2010 – August 
2011) were planned to receive the full 18 month follow-up. Participants recruited 
thereafter are offered steadily reducing follow-up periods, depending on time of 
recruitment (this was to maximise value for money, obtaining as much data as possible 
on those recruited in early phases of the trial, with shorter follow-up periods for those 
recruited in later phases). The minimum follow-up period is 9 months; the total sample 
size that could be expected to be available at each follow-up point is shown in Figure 1 
i.e. follow-ups at 12, 15 and 18 months inevitably had less participants since those most 
recently recruited could not be followed up at these time points within the funded 
resources.  
Changes to trial protocol following commencement: Following original ethical approval 
of the trial in October 2009, several amendments to the protocol were made: the 
addition of secondary measures including the CHOICE and EQ5D; addition of some 
secondary measures for an add-on hypothesis about childhood trauma at month 3; 
removal of some secondary measures at months 3, 6 and 15 in order to reduce 
participant burden; an ability to retain people if they lose capacity, which was an event 
that did not actually occur throughout the trial; a minor change to the exclusion criteria 
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to reflect the population and increase generalisability (allowing inclusion of those with 
substance dependence as long as it was not the primary diagnosis).  
Sample size: Power calculations suggested that, with 30 participants per group, using a 
t-test with a two-tailed significance level of 0.05, we had over 80% power to detect an 
effect size of 0.8 (if the significance level were altered to 15%, which may be 
appropriate for a pilot study, 30 per group provides 80% power to detect an effect size 
of 0.6). We chose a recruitment target of 80 (40 per site) in order to allow for a dropout 
rate of up to 25%. 
Blinding: Assessors were blind to treatment condition. Many strategies were employed 
to achieve blind ratings, including: research workers were not involved in the 
randomisation process; therapists were required to consider room use and diary 
arrangements in the light of potential blind-breaks; patients were reminded by assessors 
not to talk about treatment allocation. We had 13 blind breaks reported to our trial 
manager by research assistants using a standard form, representing 17.6% of 
participants; therefore, the blind was successfully maintained in 82.4% of participants. 
Of those where the blind was broken, 4/13 of these were in the TAU condition and 9/13 
in the CT condition. In cases where blinding was broken, another rater assessed the 
patient for all subsequent assessments or the ratings were discussed with a blind rater 
and consensus reached. This assessment strategy ensured that only a tiny minority of a 
total of approximately 500 assessments had their validity threatened by lack of rater 
blinding.    
Statistical methods: Analysis was agreed with the data monitoring and ethics 
committee, and the a-priori analysis plan was published 17. Analyses were undertaken in 
Stata (version 12) after completion of endpoint assessments; primary analysis was by 
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intention-to-treat. Changes in all primary and secondary outcomes were analysed using 
Stata’s xtreg command to fit random effects regression models (essentially, repeated 
measures ANCOVAs) with summed scores as dependent variables, allowing for 
attrition and the variable follow-up times introduced by the design of the trial. 
Covariates included site, gender age and the baseline value of the relevant outcome 
measure. The use of these models allowed for the analysis of all available data, on the 
assumption that data were Missing at Random (MAR) 31, conditional upon adjustment 
for centre, age, gender and observed baseline scores; the MAR assumption seems to be 
the most realistic, given the planned variation in maximum follow-up times and the 
many other factors likely to influence drop-out, and is the one routinely used in analyses 
of longitudinal trial data. We report estimated treatment effects, with their standard 
errors, significance levels and confidence intervals. For none of the outcomes was there 
any suggestion that the treatment effects were varying with time of follow-up (there 
were no significant treatment by time interactions). All treatment effects reported here 
are estimates of the effects common to all follow-up times.    
Role of the funding source: The funders and sponsors of the study had no role in study 
design, in the collection, analysis, and interpretation of data, in the writing of the report 
or in the decision to submit the paper for publication. 
Results 
We finished recruiting for the trial in June 2012 and had a final sample size of 
74, with 37 individuals in each trial arm (Manchester n = 41, Newcastle n = 33). We 
stopped before the target of 80 in accordance with our recruitment timeline, due to 
limited resources, in order to ensure that we had the possibility to obtain 9 month data 
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on all participants. The characteristics of the whole sample, and the baseline balance 
across the 2 groups, are presented in Table 1.  
In terms of feasibility of the trial, it is clear from Figure 1 that recruitment was 
relatively successful: we recruited over target in one of the two sites, and had a final 
sample of 74 participants (93% of target); our referral:randomised ratio was 2:1; only 3 
participants of 143 referrals declined participation after being assessed as eligible (2%), 
suggesting good willingness to be randomised, and to consider CT, within this 
population. Those allocated to CT received a mean of 13.3 sessions (s.d.=7.57; range 2 
to 26), each session lasting on average 1 hour (this figure does not include the 4 booster 
sessions that were available). Adherence to CT was reasonably good, with 0/37 (0%) 
not attending any sessions, and 30/37 (82.1%) receiving at least 6 or more sessions. 
Retention within the trial was reasonable, with 5/37 withdrawals in each arm, and 
missing data rates at primary end point and follow-up being just below 30%.  This rate 
of missing data, in addition to recruiting below target, obviously leads to a reduction in 
statistical power; however, this is not a major concern given that the trial was a pilot 
study. 
(TABLES 1-5 HERE) 
(FIGURE 1 HERE) 
 Table 2 shows the results of the primary outcome (PANSS) and secondary 
outcomes at each assessment point. Starting with the primary outcome (the PANSS total 
scores), it can be seen that the average scores are consistently less in the CT group than 
in the TAU controls. These are reflected in the estimates of the treatment effects 
provided in Table 3, with an estimated between-group effect size (unstandardised) for 
the PANSS total score of -6.52 (95% CI -10.79  to -2.25, p = 0.003), which equates to a 
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standardised effect size (Cohen’s d) of 0.46 (lower PANSS scores are preferable). The 
effects on the positive and general subscales are consistent with this finding, but there 
seems to be little or no effect of CT on negative symptoms. Visual inspection of the 
PANSS data makes it clear that, on average, there was not an overall deterioration in 
either group.  
Looking at the secondary outcomes, the estimated treatment effects for the 
PSYRATS scores in Table 3 are consistent with the findings for the primary outcome, 
but not all are statistically-significant. For the other outcomes, we found a significant 
effect in favour of CT for social functioning (PSP), but no differences on our measures 
of recovery (QPR), depression (BDI) or anxiety (SIAS).  
We also report numbers of participants in each group (completer-only data i.e. 
observed cases) achieving a 25%, 50%, 75% and 100% improvement/deterioration on 
adjusted PANSS total scores 32 at both 9 months and 18 months (Table 4), as has been 
recommended for trials using the PANSS33. Examining the proportion of participants 
achieving good clinical outcomes in each condition (defined using an improvement of 
>50% in adjusted PANSS total scores), we found that, at 9 months 7/22 from CT 
(31.8%) and 3/23 from TAU (13.0%) had achieved good clinical outcomes, and at 18 
months 7/17 from CT (41.2%) and 3/17 from TAU (17.6%) had achieved good clinical 
outcomes. We also examined significant deteriorations (defined using a deterioration of 
>50% in adjusted PANSS total scores); there were 2 such participants in each condition. 
We also examined serious adverse events (SAEs) as defined by the Ethics Committee; 
there were 8 in total, with 2 such events in CT (both of which occurred post therapy; 
one attempted overdose, one presenting risk to others) and 6 such events in TAU (two 
deaths, both of which were deemed unrelated to trial participation/mental health; three 
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compulsory admissions to hospital for treatment under the mental health act and one 
attempted overdose). We also examined voluntary hospital admissions during the 
treatment phase; the data regarding type, number and length of stay for hospital 
admissions is provided in table 5. There was only one admission in the follow-up phase, 
which was voluntary and lasted 4 days (this was in the CT arm). All SAEs and hospital 
admissions were in separate participants. 
We also examined the use of antipsychotic medication throughout the lifetime of 
the trial: 10/37 participants in CT were prescribed antipsychotics post-randomisation (8 
during the treatment window, 2 during the follow-up phase) versus 10/37 in TAU (9 
during the treatment window, 1 during the follow-up phase). In order to explore the 
potential contribution that medication may have contributed to individual participants, 
the extent of change in PANSS scores for those who commenced antipsychotics by 9 
and 18 months are also shown in Table 4 (the numbers who had initiated antipsychotics 
within each category being indicated with the superscript values). Of those in CT 
prescribed antipsychotics in the treatment phase, 1 was also prescribed antidepressants, 
and of those in TAU prescribed antipsychotics in the treatment phase 5 were also 
prescribed antidepressants. In addition to this, there were 9 participants in CT arm 
taking antidepressants in the treatment phase (with no new cases in follow-up) and in 
TAU we had 8 participants taking antidepressants in the treatment phase (with 2 new 
cases in follow-up). 
Discussion 
To our knowledge, this is the first RCT of CT for people with schizophrenia 
spectrum disorders who have chosen not to take antipsychotic medication. Our trial has 
shown that CT for this population does significantly reduce the severity of psychiatric 
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symptoms in this population. As well as psychiatric symptoms, CT significantly 
improved personal and social functioning and certain dimensions of delusional beliefs 
(cognitive) and voice-hearing (cognitive and physical). It did not significantly affect the 
amount of distress associated with delusional beliefs or voice-hearing, or levels of 
depression, social anxiety and self-rated recovery. A large definitive trial with a wider 
range of outcomes would answer such speculation.  
On average, neither group deteriorated over time, in a population that have been 
assumed to deteriorate without total adherence to medication 34; in fact, some 
participants in the treatment as usual condition who were not taking medication 
achieved good clinical outcomes, and more did with the addition of CT. However, it is 
also clear that some individual patients who were not taking medication did experience 
deterioration and adverse events, and that this was the case in both arms (it is also 
possible that we missed some such events, given high rates of missing data and non-
engagement with services). We also demonstrated that CT is an acceptable intervention 
for a population who are usually seen as very challenging to engage by mental health 
services, with relatively low drop-out/withdrawal rates and only 3 of 143 referrals 
refusing randomisation after assessment as eligible. 
These results are consistent with findings from clinical trials of CT for psychosis 
to date; most trials have found that severity of psychiatric symptoms can be reduced 
over a moderate timeframe in people who are taking antipsychotic medications, with an 
average effect size of 0.4 15. Our study found a similar effect size in people who had 
chosen not to take such medication (ES=0.46). Although this is a small-to-moderate 
effect size, it is interesting to note that the effect size on psychiatric symptoms observed 
in our study is similar to the median effect size reported for overall symptoms in a 
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recent large meta-analysis of 15 antipsychotic medications versus placebo (k=212; 
n=43049; ES=0.44) 8. The baseline PANSS total scores of our trial are notably higher 
than most CT for psychosis trials, suggesting that our results may be reasonably 
generalisable and are not attributable to participants being relatively well at study entry 
(our sample would be correspond to a “moderately ill” population according to 
thresholds for the PANSS35); indeed, many of the participants were viewed as 
challenging to engage by their clinical teams, with some being discharged as a result, 
and our therapists frequently had to work hard to engage them and identify a shared 
goal. CT appeared to be acceptable to this population, with zero participants attending 
no sessions and only 7/37 attending less than 6. Given that equal numbers in each arm 
commenced medication, it seems unlikely that the effects observed are due to 
medication, especially since more commenced antipsychotics during the initial 
treatment window in the TAU condition. Examination of the improvement or 
deterioration experienced by those who commenced medication (in Table 4) also 
suggests that the benefits observed are not attributable to antipsychotics. 
Our trial demonstrates methodological rigour in several ways. Importantly, we 
pre-specified the primary and secondary outcomes to be analysed, reducing the 
likelihood of type 1 errors. The use of more than one should increase generalisability to 
routine clinical service provision. However, there are some methodological difficulties 
with our trial. We did not measure treatment exposure prior to study entry (except for 
recent antipsychotic medication and CT), so are unable to allow for this in our analyses. 
We did not correct for multiple comparisons (for example, using Bonferroni’s 
correction); however, we only had one primary outcome, and given that this is a pilot 
study, it would seem overly conservative to apply a more stringent alpha for secondary 
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outcomes. It is possible that the use of acceptance into an early intervention service as 
an alternative to diagnosis as inclusion criteria may limit generalisability of our findings 
to settings that do not have such specialist teams. Similarly, the fact that we excluded 
people who were in inpatient settings also limits generalisability to those with acute 
episodes requiring admission to hospital, and those who are referred to a clinical trial 
may not be representative of all who refuse medication (although we had very few 
referred who refused to participate). Our trial is also unlikely to be generalisable to 
service users who are presenting significant risk to themselves or the community, as 
they would be likely to be managed using community treatment orders that require 
medication compliance. The lack of a control group that included non-specific factors 
such as contact time, warmth and empathy, also means that we are unable to exclude the 
possibility that the observed effects are due to such non-specific factors. Perhaps most 
importantly, our trial had low statistical power with a small sample size and a relatively 
high attrition rate (approaching 30% at our primary end points). Given the trend 
observed in trials of specific psychological therapies such as CT for psychosis, which 
have shown that effect sizes are reduced when indices of study quality (such as adequate 
statistical power and active comparators) are controlled for 15, it is likely that our effect 
sizes are inflated. Therefore, an adequately powered definitive randomised controlled 
trial is required. A larger definitive trial would allow for analysis of factors such as 
therapist effects and subgroups (e.g. participants not taking any medications).  
There are several clinical implications arising from this study, although they 
need to be considered cautiously, given the limitations of a pilot study. Given that the 
largest factor in our participants choices not to take antipsychotics was side effects 17, it 
is important to be able to have alternative evidence-based treatments for people who 
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choose not to take antipsychotics. Given that we found CT reduced severity of 
psychiatric symptoms and increased social functioning in people with schizophrenia 
spectrum disorders without the use of antipsychotic medication, such an approach may 
provide the benefits of symptom-based improvement without the associated risks of 
serious side effects. Thus, it may be possible to offer informed choices to service users 
who retain decision making-capacity if there is no risk to self or others (a 
comprehensive risk assessment would be required to inform this). We are not 
advocating that people who derive benefit from antipsychotic medication should 
consider discontinuation; rather, we are advocating for evidence-based alternatives for 
those who choose not to on the basis of side effects or inefficacy (it is important to 
consider that this may be as high as half of all service users with schizophrenia 
spectrum disorders5). A collaborative approach to decision making may also result in a 
better response for those who choose to take antipsychotics, since the quality of 
relationship with the prescribing clinician is associated with attitudes to and adherence 
with medication 36; in this context, it is also worth noting that 20 of our participants 
started antipsychotic medication at some point after having originally chosen not to. 
Consistent with this approach, the recently published NICE guidelines for psychosis and 
schizophrenia in children and young people recommend that service users and carers 
should be entitled to choose psychosocial interventions, such as CT, in the absence of 
antipsychotics 37. 
Research in Context: 
Systematic Review: Recent systematic reviews and meta-analyses 1 15 37 have found that, 
while there is robust evidence that CT for psychosis in addition to antipsychotics is 
 21 
superior to treatment as usual, there are no randomised controlled trials of CT in people 
with psychotic disorders who are not taking antipsychotics. 
Interpretations: Our study suggests that CT is an acceptable, safe and effective 
treatment for people who choose not to take antipsychotics, although a larger definitive 
trial is required, given that this is a pilot trial. 
 
 
Acknowledgements 
This article outlines independent research funded by the National Institute for Health 
Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant 
Reference Number PB-PG- 1208-18053). The views expressed are those of the 
author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. 
We thank the Mental Health Research Network and the OpenCDMS team for their 
support and assistance. We would also like to thank the independent members of our 
Data Monitoring and Ethics Committee (Professor David Kingdon and Professor John 
Norrie). Graham Dunn had full access to all of the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the data analysis. 
 
Contributors: All authors were involved in the design of the study and the ongoing 
management and delivery of the trial, and contributed to drafts of this manuscript. AM, 
the chief investigator, conceived of the study, prepared the protocol, contributed to the 
training and supervision of the therapists and supervision of the researchers, had overall 
responsibility for the day to day running of the study, interpreted the data, and took the 
lead on writing this report. He is the guarantor for the study. AM, DT, PH, AB, RD, 
NC, TC, PC, TG and VL participated in preparation of the treatment protocol and the 
training and supervision of the therapists. DT and AB managed the additional site. AM, 
 22 
MP, HS and DT trained the researchers in the psychiatric interviews, supervised and 
monitored standards of psychiatric interviewing and assessment throughout the trial. DT 
also advised on diagnostic ratings and exclusions. MP was the trial manager. She 
supervised and coordinated recruitment, contributed to training of research staff, and 
was responsible for staff management and overall coordination of the study. HS, LD, 
AC, KI and ST were responsible for maintaining reliability of assessment procedures 
and data collection. GD was the trial statistician. He advised on randomisation and all 
statistical aspects of the trial, developed the analysis plan, and performed the statistical 
analyses and is guarantor in this respect. LD was the trial health economist. RB was a 
service user consultant involved in all aspects of the study.  
 23 
References 
1. National Institute for Clinical Excellence. Schizophrenia: core interventions in the 
treatment and management of schizophrenia in primary and secondary care. 
UK: NICE, 2009. 
2. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 
11-year follow-up of mortality in patients with schizophrenia: a population-
based cohort study (FIN11 study). Lancet 2009;374(9690):620-627. 
3. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic 
drugs versus placebo for relapse prevention in schizophrenia: a systematic 
review and meta-analysis. The Lancet 2012;379(9831):2063-2071. 
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz M, Rosenheck R, Perkins D, et al. 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New 
England Journal of Medicine 2005;353:1209-1223. 
5. Lacro JP, Dunn LB, Dolder CR. Prevalence of and risk factors for medication 
nonadherence in patients with schizophrenia: a comprehensive review of recent 
literature. Journal of Clinical Psychiatry 2002;63:892-909. 
6. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic 
medication: a content analysis of Internet data. Acta Psychiatrica Scandinavica 
2009;120(2):102-111. 
7. Lepping P, Sambhi RS, Whittington R, Lane S, Poole R. Clinical relevance of 
findings in trials of antipsychotics: systematic review. The British Journal of 
Psychiatry 2011;198(5):341-345. 
8. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative 
efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-
treatments meta-analysis. The Lancet 2013;S0140-6736(13)60733-3. 
9. Correll CU, Hert MD. Antipsychotics for acute schizophrenia: making choices. The 
Lancet 2013. 
10. Ho B-C, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term 
Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-
Episode Schizophrenia. Arch Gen Psychiatry 2011;68(2):128-137. 
11. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs 
and the Risk of Sudden Cardiac Death. New England Journal of Medicine 
2009;360(3):225-235. 
12. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. 
Non-pharmacological management of antipsychotic-induced weight gain: 
systematic review and meta-analysis of randomised controlled trials. The British 
Journal of Psychiatry 2008;193(2):101-107. 
13. Owens GS, Richardson G, David AS, Szmukler G, Hayward P, Hotopf M. Mental 
capacity to make decisions on treatment in people admitted to psychiatric 
hospitals: cross sectional study. Britsih Medical Journal 2008;337:448. 
14. Warner L, Mariathasan J, Lawton-Smith S, Samele C. A Review of the Literature 
and Consultation on Choice and Decision-making for Users and Carers of 
Mental Health and Social Care Services. London: King's Fund/Sainsbury Centre 
for Mental Health, 2006. 
15. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive Behavior Therapy for 
Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor. 
Schizophrenia Bulletin 2008;34:523-537. 
 24 
16. Morrison AP, Hutton P, Wardle M, Spencer H, Barratt S, Brabban A, et al. 
Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking 
antipsychotic medication: An exploratory trial. Psychological Medicine 
2012;42(5):1049-1056. 
17. Morrison AP, Wardle M, Hutton P, Davies L, Dunn G, Brabban A, et al. Assessing 
Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample 
characteristics of the ACTION trial. Psychosis 2013;5(1):82-92. 
18. Ainsworth JD, Harper RS. The PsyGrid Experience: Using Web Services in the 
Study of Schizophrenia. International Journal of Healthcare Information 
Systems and Informatics 2007;2:1-20. 
19. Morrison AP. The interpretation of intrusions in psychosis: An integrative cognitive 
approach to hallucinations and delusions. Behavioural and Cognitive 
Psychotherapy 2001;29:257-276. 
20. Morrison AP, Renton JC, Dunn H, Williams S, Bentall RP. Cognitive Therapy for 
Psychosis: a Formulation-based Approach. London: Brunner-Routledge, 2004. 
21. Kingdon D, Turkington D. Cognitive therapy for schizophrenia. New York: 
Guilford Press, 2005. 
22. Blackburn IM, James I, Milne D, Baker CA, Standart S, Garland A, et al. The 
revised cognitive therapy scale (CTS-R): psychometric properties. Behavioural 
and Cognitive Psychotherapy 2001;29:431-446. 
23. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale 
(PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-276. 
24. Kay SR, Opler LA, Fiszbein A. Reliability and validity of the Positive and Negative 
Syndrome Scale for schizophrenics. Psychiatry Research 1988;23:276-286. 
25. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of 
hallucinations and delusions: The psychotic symptoms rating scales 
(PSYRATS). Psychological Medicine 1999;29:879-889. 
26. Neil ST, Kilbride M, Pitt L, Welford M, Nothard S, Sellwood W, et al. The 
Questionnaire about the Process of Recovery (QPR): A research instrument 
developed in collaboration with service users. Psychosis 2009;1:145-155. 
27. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability 
and acceptability of a new version of the DSM-IV Social and Occupational 
Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta 
Psychiatrica Scandinavica 2000;101(4):323-329. 
28. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in 
medical inpatients with the Beck Depression Inventory for Primary Care. 
Behaviour Research and Therapy 1997;35:785-791. 
29. Mattick RP, Clarke JC. Development and validation of measures of social phobia 
scrutiny fear and social interaction anxiety. Behavior Research and Therapy 
1998;36:455-470. 
30. Peters L. Discriminant validity of the Social Phobia and Anxiety Inventory (SPAI), 
the Social Phobia Scale (SPS) and the Social Interaction Anxiety Scale (SIAS). 
Behaviour Research and Therapy 2000;38(9):943-950. 
31. Little RJA, Rubin DB. Statistical Analysis with Missing Data. London: John Wiley 
and Sons, 2002. 
32. Leucht S, Kissling W, Davis JM. The PANSS Should Be Rescaled. Schizophrenia 
Bulletin 2010;36:461-462. 
 25 
33. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in 
antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. 
Neuropsychopharmacology 2007;32(9):1903-1910. 
34. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, et al. 
Risperidone Nonadherence and Return of Positive Symptoms in the Early 
Course of Schizophrenia. Am J Psychiatry 2011;168(3):286-292. 
35. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the 
PANSS mean? Schizophrenia research 2005;79(2):231-238. 
36. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes 
Toward Antipsychotic Medication: The Impact of Clinical Variables and 
Relationships With Health Professionals. Arch Gen Psychiatry 2005;62(7):717-
724. 
37. National Institute for Clinical Excellence. Psychosis and schizophrenia in children 
and young people: Recognition and management. UK: NICE, 2013. 
 
 
 26 
 Figure 1: CONSORT Diagram for entry to study 
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Referred N = 143 
Randomised N = 74 
Not eligible N = 69 
 
Excluded (N = 48) 
 Below threshold on PANSS = 22 
 Evidence of organic impairment = 2 
 In receipt of antipsychotic medication 
currently or within  the past 6 months = 10 
 Received CBT of psychosis or any other 
disorder within the past 2 years = 1 
 Current inpatient care = 2 
 Absence of care coordination = 3 
 Absence of a primary diagnosis of psychosis = 
5 
 Unable to engage before the end of the trial = 
3 
 
Decline involvement (N = 21): 
 Before assessment of eligibility occurred = 18 
 After assessed as eligible = 3  
Allocated to CT plus monitoring (n= 37) 
 
 
 
Allocated to monitoring only (n= 37) 
 
 
Sites n= 2 
Number allocated per site: Manchester (n= 21), 
Newcastle (n = 16) 
 
 
 
Sites n= 2, therapists n = 9 
Number allocated per therapist per site: 
Manchester (n=18, 2), Newcastle (n =3, 4, 2, 0, 
3, 2, 3) 
 
 
 
3 months (possible n = 37) 
Lost to follow-up (n = 7) 
Discontinued (withdrawn) (n = 2) 
 
 
6 months (possible n = 37) 
Lost to follow-up (n = 8) 
Discontinued (withdrawn) (n = 4) 
 
 9 months (possible n = 37) 
Lost to follow-up (n = 8) 
Discontinued (withdrawn) (n = 4) 
 
12 months (possible n = 34) 
Lost to follow-up (n = 12) 
Discontinued (withdrawn) (n = 4) 
 
 
 
 
15 months (possible n = 30) 
Lost to follow-up (n = 12) 
Discontinued (withdrawn) (n = 4) 
 
 
 
3 months (possible n = 37) 
Lost to follow-up (n = 10) 
Discontinued (withdrawn) (n = 2) 
 
 
 
6 months (possible n = 37) 
Lost to follow-up (n = 14) 
Discontinued (withdrawn) (n = 3) 
 
 9 months (possible n = 37) 
Lost to follow-up (n = 6) 
Discontinued (withdrawn n = 3)  
Discontinued (deceased n =1) 
 
 
 
 
12 months (possible n = 34) 
Lost to follow-up (n = 7) 
Discontinued (withdrawn) (n = 4) 
Discontinued (deceased) (n = 1) 
 
15 months (possible n = 30) 
Lost to follow-up (n = 8) 
Discontinued (withdrawn) (n = 3) 
Discontinued (deceased) (n = 2) 
 
 
 
18 months (possible n = 26) 
Lost to follow-up (n = 3) 
Discontinued (withdrawn) (n = 5) 
 
 
18 months (possible n = 25) 
Lost to follow-up (n = 3) 
Discontinued (withdrawn) (n = 2) 
Discontinued (deceased) (n = 2) 
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Table 1: Baseline characteristics: Means and SDs for variables for total sample and for 
each group  
 
 Whole sample 
(N=74) 
CT plus TAU (N=37) TAU only (N=37) 
Age    
 
 
Male: Female ratio (n)  
 
PANSS Total 
 
 
PANSS Positive 
 
 
PANSS Negative 
 
 
PANSS General  
  
 
PSYRATS Unusual Beliefs - 
Cognitive 
 
PSYRATS – Unusual Beliefs - 
Emotional 
 
PSYRATS Voices - Cognitive 
 
 
PSYRATS Voices - Emotional 
 
 
PSYRATS Voices - Physical 
 
 
PSP 
 
 
QPR Intrapersonal 
 
 
QPR Interpersonal 
 
 
BDI-PC total  
  
 
 SIAS total 
 
   
PANSS G12 (Insight) 
 
 
PANSS Insight > 3: moderate 
or higher problems (n) 
31.47 
(12.27) 
 
39:35 
 
71.55 
(13.76) 
 
20.89 
(4.91) 
 
14.31 
(4.61) 
 
36.18 
(7.70) 
 
10.27 
(3.59) 
 
5.08 
(2.58) 
 
6.52 
(5.29) 
 
6.90 
(6.23) 
 
6.47 
(5.29) 
 
53.43 
(16.57) 
 
33.61 
(12.42) 
 
12.76 
(2.82) 
 
10.011 
(4.68) 
 
40.77 
(18.03) 
 
3.12  
(1.66) 
 
34 
32.95 
(13.11) 
 
17:20 
 
70.24    
(13.75) 
 
20.30 
(5.22) 
 
13.54 
(3.17) 
 
36.41 
(7.94) 
 
10.11       
(4.18)              
 
5.17        
(2.69)              
 
5.28       
(5.13)              
 
5.86        
(6.43)             
 
5.62        
(5.40)             
 
56.84 
(16.45) 
 
34.19       
(12.17)             
 
13.05       
(2.77)              
 
10.54 
(5.21) 
 
40.43 
(19.76) 
 
3.03  
(1.67) 
 
17 
29.68 
(11.95) 
 
22:15 
 
73.27    
(13.42) 
 
21.65 
(4.47) 
 
15.49 
(5.26) 
 
36.14   
(7.05) 
 
10.43       
(2.91)              
 
5.00        
(2.51)              
 
7.73       
(5.23)              
 
7.92        
(5.93)             
 
7.37        
(5.10)             
 
50.03 
(16.19) 
 
32.97       
(12.85)             
 
12.44       
(2.88)              
 
9.41 
(4.03) 
 
45.15 
(15.19) 
 
3.20 
(1.67) 
 
17 
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 30 
 
Variable 
3 
CT 
 
N=37 
months 
TAU 
 
N=37 
6 
CT 
 
N=37 
months 
TAU 
 
N=37 
9 
CT 
 
N=37 
months 
TAU 
 
N=37 
12 
CT 
 
N=34 
months 
TAU 
 
N=34 
15 
CT 
 
N=30 
months 
TAU 
 
N=30 
18 
CT 
 
N=26 
months 
TAU 
 
N=25 
 
PANSS total 
 
62.93 
(13.72) 
N=28 
 
 
72.88 
(15.56) 
N=24 
 
59.96 
(14.47) 
N=23 
 
66.95 
(11.70) 
N=19 
 
57.95 
(14.99) 
N=22 
 
63.26 
(13.21) 
N=23 
 
58.56 
(18.85) 
N=18 
 
68.33 
(15.03) 
N=21 
 
54.68 
(14.61) 
N=19 
 
69.94 
(14.35) 
N=16 
 
56.47 
(18.22) 
N=17 
 
71.24 
(20.35) 
N=17 
PANSS positive 18.14 
(5.34) 
N=28 
21.71 
(5.83) 
N=24 
17.04 
(5.36) 
N=23 
18.32 
(4.40) 
N=19 
16.00 
(5.94) 
N=22 
17.00 
(4.85) 
N=23 
16.32 
(7.94) 
N=19 
18.62 
(5.26) 
N=21 
14.05 
(5.36) 
N=19 
19.44 
(5.75) 
N=16 
14.63 
(6.18) 
N=19 
18.83 
(7.26) 
N=18 
 
PANSS negative 
 
13.00 
(3.16) 
N=28 
 
14.88 
(5.77) 
N=24 
 
12.48 
(3.63) 
N=23 
 
13.95 
(3.76) 
N=19 
 
12.5 
(3.38) 
N=22 
 
14.26 
(4.21) 
N=23 
 
12.61 
(4.24) 
N=18 
 
15.95 
(5.89) 
N=21 
 
12.05 
(3.85) 
N=19 
 
16.19 
(5.49) 
N=16 
 
12.53 
(2.83) 
N=17 
 
16.59 
(6.65) 
N=17 
 
PANSS general 
 
31.79 
(7.89) 
N=28 
 
36.29 
(8.26) 
N=24 
 
30.43 
(8.63) 
N=23 
 
34.68 
(7.17) 
N=19 
 
29.45 
(7.68) 
N=22 
 
32.00 
(6.98) 
N=23 
 
29.78 
(7.95) 
N=18 
 
33.76 
(7.80) 
N=21 
 
28.58 
(7.71) 
N=19 
 
34.31 
(7.10) 
N=16 
 
29.22 
(10.51) 
N=18 
 
35.82 
(9.74) 
N=17 
 
QPR Intrapersonal 
 
 
38.83 
(12.06) 
N=24 
 
33.26  
 (14.03) 
N=23                
 
36.10 
(16.77) 
N=21 
 
34.74  
 (11.62)  
N=19               
 
38.41 
(14.48) 
N=27 
 
36.88 
(9.17) 
N=24                   
  
40.06 
(16.88) 
N=18 
 
35.50 
(10.10) 
N=18                  
 
44.06 
(16.24) 
N=18 
 
31.43 
 (13.37) 
N=14                  
 
42.41 
(19.60) 
N=17 
 
33.94 
(9.57) 
N=16                   
             
QPR Interpersonal 12.13       12.57       13.00       12.05       12.96       11.71       14.11       13.11       13.11       11.29       13.77       12.31       
 (2.66)   
N=24            
(3.58) 
N=23              
(3.88)  
N=22             
(4.89) 
N=21              
(3.84) 
N=27              
(2.69) 
N=24              
(3.50) 
N=18              
(2.52) 
N=18             
(4.91) 
N=18              
(4.07) 
N=14              
(4.75)  
N=17             
(1.85) 
N=16              
 
PSP 
 
 
 
BDI 
 
 
 
SIAS 
 
 
 
59.81 
(16.55) 
N=27 
 
7.83 
(5.58) 
N=24 
 
35.18 
(18.75) 
N=22 
 
49.70 
(14.46) 
N=24 
 
9.65 
(4.69) 
N=23 
 
44.53 
(13.21) 
N=19 
 
59.74 
(17.88) 
N=23 
 
7.57 
(5.89) 
N=21 
 
37.63 
(18.40) 
N=19 
 
51.89 
(16.09) 
N=19 
 
7.37 
(3.61) 
N=19 
 
40.78 
(12.88) 
N=18 
 
65.00 
(12.75) 
N=23 
 
6.35 
(5.93) 
N=26 
 
31.71 
(16.34) 
N=24 
 
56.74 
(15.02) 
N=23 
 
7.14 
(3.35) 
N=21 
 
40.48 
(13.88) 
N=21 
 
65.37 
(17.63) 
N=1 
 
7.44 
(6.34) 
N=18 
 
30.00 
(22.38) 
N=15 
 
52.95 
(15.50) 
N=21 
 
7.00 
(3.54) 
N=17 
 
41.86 
(14.87) 
N=14 
 
65.84 
(18.22) 
N=19 
 
4.50 
(4.05) 
N=16 
 
28.59 
(18.21) 
N=17 
 
53.53 
(18.75) 
N=15 
 
7.38 
(4.29) 
N=13 
 
45.27 
(16.44) 
N=11 
 
64.74 
(20.24) 
N=19 
 
5.50 
(5.63) 
N=16 
 
31.31 
(20.87) 
N=16 
 
55.94 
(20.29) 
N=18 
 
7.38 
(5.16) 
N=16 
 
44.06 
(18.21) 
N=16 
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Table 2: Means, SDs and N for primary and secondary outcome variables at 3-, 6-, 9-, 12-, 15- and 18 months 
 
 
 
PSYRATS Delusions - 
Cognitive 
 
 
PSYRATS Delusions - 
Emotional 
 
 
PSYRATS Voices – 
Cognitive 
 
 
PSYRATS Voices – 
Emotional 
 
 
PSYRATS Voices - 
Physical 
 
7.82       
(4.97)              
N=27 
 
3.85        
(3.21)  
N=27             
 
3.52 
(4.78) 
N=27 
 
3.41 
(5.40)  
N=27 
 
4.37 
(5.49)   
N=27                                                      
 
9.57       
(3.75)  
N=23             
 
4.78        
(2.88)   
 N=23           
 
6.78 
(5.78) 
N=23 
 
5.96 
(6.09) 
N=23 
 
7.04 
(5.92)       
N=23                      
 
7.78       
(4.88)    
 N=23          
 
3.61        
(3.24) 
N=23              
 
2.26 
(3.89)  
N=23 
 
2.35 
(4.25) 
N=23 
 
3.00        
(4.84) 
N=23                         
 
8.00       
(3.41)   
N=18            
 
3.28        
(3.14)     
N=18          
 
6.00 
 (5.45)   
N=19 
 
4.26 
(5.95) 
N=19 
 
5.37 
(5.20) 
N=19                                 
 
6.63       
(5.32)   
N=24            
 
3.21        
(3.36)     
N=24          
 
2.73 
(4.46) 
N=26 
 
2.81 
(5.02)  
N=26 
 
3.31        
 (4.76) 
N=26                                                
 
7.28 
(4.99)  
N=25             
 
2.92        
(2.75)  
N=25             
 
4.82 
(5.29)  
N=27 
 
5.07 
(5.90) 
N=27 
 
4.82 
(5.41) 
N=27                                  
 
6.00       
(5.75)  
N=19             
 
3.05        
(3.37)   
N=19            
 
3.25 
(3.70)   
N=20 
 
3.74 
(5.53) 
N=19 
 
4.35  
(4.67) 
N=20                       
 
8.63       
(4.21)  
N=19             
 
4.11        
(2.94) 
N=19              
 
5.37       
(5.92)  
N=19 
 
4.26 
(6.04)  
N=19 
 
5.76 
(5.93) 
N=21                             
 
3.47       
(4.66)   
N=19            
 
1.26        
(2.51)  
N=19             
 
2.42 
(3.88) 
N=19 
 
2.00  
(3.84) 
N=19 
 
2.58 
(4.02) 
N=19                                          
 
8.81       
(4.36)   
N=16            
 
3.38        
(2.68)   
N=16            
 
5.94 
(5.13) 
N=17 
 
5.12 
(6.12)  
N=17 
 
 5.94 
 (4.89) 
N=17                      
 
5.32       
(5.39)  
N=19             
 
2.21        
(2.72)  
N=19             
 
0.79 
 (2.37) 
N=19 
 
0.50 
(2.12) 
N=18 
 
1.11 
(3.32)  
N=19                                                
 
7.18       
(4.76)  
N=17             
 
3.47    
(2.63)  
N=17 
 
5.65  
(5.36)   
N=17 
 
6.00 
(6.49)  
N=18 
 
6.83  
(6.21) 
N=18                                                   
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Table 3  Treatment effect estimates (common to all follow-up times) 
 
Primary Outcome     Estimate* s.e.  p-value 95% confidence interval 
 
PANSS total         -6.52     2.18   0.003  -10.79 to   -2.25 
PANSS positive       -2.22     0.91     0.015    -4.00   to   -0.44 
PANSS negative     -1.02     0.67  0.130     -2.35   to   +0.30 
PANSS general     -3.63     1.21  0.003     -5.99   to   -1.27 
 
Secondary Outcomes 
PSYRATS unusual beliefs cognitive   -2.08     0.82  0.011     -3.69   to   -0.47 
PYSRATS unusual beliefs emotion   -0.70     0.51  0.170     -1.71   to   +0.30 
PSYRATS voices cognitive    -2.10     0.95  0.028     -3.96   to   -0.23 
PSYRATS voices emotion    -1.44     1.06  0.174     -3.52   to   +0.64 
PSYRATS voices physical    -1.76     0.89  0.048     -3.51   to   -0.02 
 
QPR *       +3.32     1.90  0.080     -0.39   to    +7.04 
PSP*       +5.47    2.70  0.043      +0.18  to  +10.77 
BDI       -0.73     0.79  0.357     -2.29   to   +0.83 
SIAS       -1.63     3.17  0.607     -7.84   to   +4.58 
 
 * Negative estimates indicate that, on average, scores for the CT group were lower than in TAU, except on these items, where a higher 
score is preferable. 
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Table 4: Number of participants achieving improvement/deterioration on adjusted PANSS total scores at 9 and 18 months 
 
 
 
 
CT 
(18m)  
17 0 0 1 1 0 0 4(2) 4 6(2) 1 
TAU 
(18m) 
17 0 0 2 2(2) 3(1) 1 4(2) 2 2(1) 1 
 
NOTE: superscript numbers (n) indicate the number of participants who had commenced antipsychotic medication, of 
the total number N within each change category. 
 
 
 
 
 
 
 
 
  Increase (deterioration)  Reduction (improvement) 
 Total 
N 
100%+ 75-
100% 
50-
74% 
25-
49% 
0-
24% 
0% 
change 
0-
24%  
25-
49%  
50-
74%  
75-
100%  
CT 
(9m)  
22 1(1) 0 0 1(1) 3 2(1) 3(1) 5(2) 4 3(2) 
TAU 
(9m) 
23 0 0 0 2 2(1) 2(1) 9(3) 5(2) 2 1 
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Table 5 Hospital admissions during the treatment phase  
  
  
 CT plus TAU TAU 
N 
participants 
admitted 
Mean no. 
days in 
hospital 
(SD) 
N 
participants 
admitted  
Mean no. 
days in 
hospital  
(SD) 
Voluntary admission 4 12.25 
(9.54) 
1 27.00 
(0.00) 
Compulsory admission 0 0.00  
(0.00) 
3 42.00  
(22.65) 
